Anti-CCR4 Monoclonal Antibody Mogamulizumab Followed by the GDP (Gemcitabine, Dexamethasone and Cisplatin) Regimen in Primary Refractory Angioimmunoblastic T-Cell Lymphoma
Anti-CCR4 Monoclonal Antibody Mogamulizumab Followed by the GDP (Gemcitabine, Dexamethasone and Cisplatin) Regimen in Primary Refractory Angioimmunoblastic T-Cell Lymphoma
复制标题
抗 CCR4 单克隆抗体 Mogamulizumab 继 GDP（吉西他滨、地塞米松和顺铂）方案治疗原发性难治性血管免疫母细胞 T 细胞淋巴瘤
DOI：
10.1159/000444518
复制
发表时间：
2017
期刊：
影响因子：
3.3
通讯作者：
Kinoshita Tomohiro
中科院分区：
文献类型：
--
作者：
Kato Harumi;Yamamoto Kazuhito;Higuchi Yusuke;Yamamoto Hideyuki;Saito Toko;Taji Hirofumi;Yatabe Yasushi;Nakamura Shigeo;Kinoshita Tomohiro
对于复发或难治性血管免疫母细胞t细胞淋巴瘤（AITL）的老年患者，几乎没有有效的挽救治疗选择。抗ccr4抗体mogamulizumab通过抗体依赖的细胞毒性活性起作用，降低调节性T细胞，并在癌症患者中唤起抗肿瘤免疫。我们报告了一位78岁的难治性AITL患者接受了一种新的免疫化疗，包括序贯mogamulizumab给药，然后是GDP（吉西他滨、地塞米松和顺铂）方案。在mogamulizumab单药治疗后部分缓解的患者中，可以观察到GDP方案的良好巩固效果。该方案显示出可接受的毒性特征，没有严重的自身免疫，并且对原发性难治性AITL的老年患者有预期的治疗反应。该临床病例是文献中首次报道的使用莫加珠单抗治疗原发性难治性AITL的补救性化疗。
There are few effective options for salvage therapy in elderly patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL). The anti-CCR4 antibody mogamulizumab works via antibody-dependent cytotoxic activity, reduces regulatory T cells, and evokes antitumor immunity in cancer patients. We report a 78-year-old patient with refractory AITL receiving a new immunochemotherapy consisting of sequential mogamulizumab administration followed by the GDP (gemcitabine, dexamethasone and cisplatin) regimen. A favorable consolidative effect of the GDP regimen could be observed in the patient who had partial remission after administration of mogamulizumab monotherapy. The regimen showed an acceptable toxicity profile without serious autoimmunity and an expected treatment response for the elderly patient with primary refractory AITL. This clinical case is the first report of salvage chemotherapy including mogamulizumab for primary refractory AITL described in the literature.